Thymosin Alpha-1
A 28-amino-acid thymic peptide studied for T-cell maturation, innate immune tone, and host-defense immunology.
What Thymosin Alpha-1 is
Thymosin alpha-1 (Tα1) is a 28-amino-acid peptide originally isolated from thymic tissue and later produced synthetically. It has been investigated for decades as an immunomodulatory molecule that can influence T-cell maturation, dendritic-cell function, and innate immune signaling. In some countries a pharmaceutical form (thymalfasin) has been used clinically; that regulated product context is separate from bulk research-grade peptide supply.
The research literature spans viral immunology, sepsis adjunct models, vaccine-response biology, and cancer-immune interaction studies. Reviews summarize a large cumulative clinical-trial footprint and generally describe a favorable tolerability profile in studied settings, while also noting heterogeneity of indications and study quality.
Research-grade thymosin alpha-1 is Research Use Only. It is not an FDA-approved U.S. drug product for general therapeutic marketing in this RUO context, and it is not for human consumption. Dosage figures below are literature references for education only.
Thymosin Alpha-1 has been studied in human trials, which is not true of most compounds in this library. The figures below come from that work.
How it works
Tα1 interacts with innate immune pattern-recognition pathways, including Toll-like receptor-related signaling in dendritic cells and other antigen-presenting cells. Downstream effects reported in the literature include enhanced T-cell differentiation and function, modulation of cytokine patterns, support of NK-cell activity, and context-dependent restoration of immune competence in suppressed states. It is better described as a multi-node immune modulator than as a single-receptor hormone mimetic.
Where this compound shows up in research
Immunologists, infectious-disease researchers, and translational oncology groups are the primary audience. Additional work appears in aging-immunity and vaccine-response laboratories interested in thymic peptide biology.
What the research examines
Each tag marks a field where this compound appears in research. Appearing in a literature is not the same as working.
How it appears in the literature
How these amounts appear in the literature. Read the study before reading the number.
| Research context | Reported amount | Frequency | Route |
|---|---|---|---|
| Commonly cited thymalfasin / Tα1 research and clinical-literature exposure | 1.6 mg – 3.2 mg | twice weekly | subcutaneous |
| Alternate research schedules summarized in reviews | 900 mcg – 1.6 mg | two to seven times weekly depending on protocol | subcutaneous |
Handling & storage
Keep lyophilized Tα1 cold, dry, and light-protected. After reconstitution, refrigerate and handle as a labile peptide according to the laboratory beyond-use protocol.
Notes on combined research
Research designs sometimes evaluate thymosin alpha-1 alongside antivirals, checkpoint-oriented oncology regimens, or other immune modulators when the question is host-response augmentation. It is mechanistically distinct from tissue-repair peptides such as TB-500, so combinations are usually immunology-driven rather than recovery-stack driven.
Thymosin Alpha-1 questions
Many clinical and translational papers reference about 1.6 mg subcutaneously twice weekly for thymalfasin-style regimens. Other schedules exist; methods sections are the authoritative source.
No. Thymosin alpha-1 is an immunomodulatory thymic peptide. TB-500 relates to thymosin beta-4 actin biology. They are different molecules with different research stories.
Literature describes effects on T-cell maturation, dendritic-cell activation via innate receptors, cytokine balance, and host-defense readiness in suppressed or challenged states.
Research-grade material is RUO and not for human consumption. Pharmaceutical thymalfasin has been used in some countries under local regulatory frameworks, which is a separate product class.
Because multiple studies and reviews examine whether immune reconstitution or immune modulation with Tα1 changes host response in viral disease and sepsis models.
As lyophilized peptide in multi-milligram vials that are reconstituted before in vitro or in vivo experimental use.
No. Many protocols use repeated dosing over weeks because immune endpoints accumulate across a course even when plasma residence time per dose is short.
Read the research yourself
Each citation was checked against PubMed before it went on this page. If we cannot link it, we do not claim it.
- Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials.PubMed
- Thymosin alpha 1: A comprehensive review of the literature.PubMed
- Immune Modulation with Thymosin Alpha 1 Treatment.PubMed
- Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis.PubMed